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Abstract
Background: Amino acids have been reported to act as modulators of various regulatory processes and to provide
new therapeutic applications for either the prevention or treatment of metabolic disorders. The purpose of the
present study is to investigate the effects of single oral dose administration and a continuous treatment of L-
tryptophan (L-Trp) on the regulation of blood pressure and glucose metabolism in stroke-prone spontaneously
hypertensive rats (SHRSP).
Methods: First, male 9-week-old SHRSP were administered 100 mg L-Trp·kg
-1 body weight in saline to the L-Trp
group and 0.9% saline to the control group via a gastric tube as a single oral dose of L-Trp. Second, three groups
of SHRSP were fed an AIN-93M-based diet supplemented with L-tryptophan (L-Trp) (0, 200, or 1000 mg·kg
-1 diet)
for 3 weeks as continuous treatment of L-Trp.
Results: Single oral dose administration of L-Trp improved blood pressure, blood glucose, and insulin levels. Blood
pressure, blood glucose, and insulin levels improved significantly in the L-Trp treatment groups. The administration
of L-Trp also significantly increased plasma nitric oxide and serotonin levels.
Conclusion: L-Trp by both single oral dose administration and continuous treatment improves glucose metabolism
and blood pressure in SHRSP.
Introduction
Our modern lifestyle is prone to overnutrition and lack
of physical activity, which dramatically increases the
incidence of metabolic disorders, including diseases
associated with obesity, diabetes mellitus, dyslipidemia,
and hypertension [1]. Currently, much effort is being
invested in detecting bioactive compounds in foods that
can decrease the risk of metabolic disorders, including
dietary antioxidants such as vitamin E, vitamin C, caro-
tenoids, and polyphenols, which are known to decrease
the risk factors of cardiovascular diseases [2]. Taking a
different approach to prevent metabolic disorders, nutri-
tionists and food technologists have recommended sev-
eral strategies, such as the intake of functional foods,
food supplements, and medicines [3].
Recent research has demonstrated that certain amino
acids, such as L-tryptophan (L-Trp), can regulate phy-
siological processes and may be the basis for novel ther-
apeutics to prevent or treat chronic diseases. Previous
studies have shown that L-Trp lowers blood pressure
(BP) and affects the level of serotonin in the brains of
spontaneously hypertensive animals [4]; however, the
relationship between decreased BP and serotonin is
unclear. In addition, L-Trp affects glucose metabolism
in rat hepatocytes [5].
Serotonin is a monoaminergic neurotransmitter that
affects vasoconstriction, intestinal motility, primary
hemostasis, liver repair, and the control of the T cell-
mediated immune system. The first step in the synthesis
of serotonin from tryptophan is the enzyme tryptophan
hydroxylase, which is also the rate-limiting enzyme in
serotonin’sb i o s y n t h e s i s[ 6 - 9 ] .I na n i m a l s ,t h ee f f e c to f
serotonin levels on glycemia is unclear. Studies have
reported that an increase in serotonin concentrations
can decrease blood glucose levels via the induction of
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showed that serotonin may have a hyperglycemic effect
[12]. The exact mechanism underlying this hypoglyce-
mic effect is not well understood, although it may be
mediated by the serotonin receptor in rats [13].
As a result, the purpose of the present study is to
investigate the effects of single oral dose administration
and a continuous treatment of L-tryptophan (L-Trp) on
the regulation of blood pressure and glucose metabolism
in stroke-prone spontaneously hypertensive rats
(SHRSP), an animal model of hypertension-related dis-
orders and insulin resistance in humans [14,15]. Specifi-
cally, we determined whether single oral dose
administration or continuous treatment of L-Trp
affected the blood pressure and glucose metabolism in
these rats. This study further elucidated the underlying
mechanisms of the effects of L-Trp on the parameters
of metabolic disorders in SHRSP.
Methods
Animals, experimental design, and ethical guidelines
Male Izumo strain SHRSP was purchased from Japan
SLC, Inc. (Shizuoka, Japan). The rats were housed in
individual stainless steel cages in a controlled environ-
ment (23 ± 2°C, 50 ± 10% humidity, and 12-h light-dark
cycle). All experimental procedures in this study were
conducted in accordance with Japanese government
guidelines (2005) and approved by the Animal Research-
Animal Care Committee of Tohoku University (No. 20-
dounou-21). This committee also supervised the care
and use of the rats in this study.
Blood pressure measurements
BP was measured with a BP meter (MK-2000, Muroma-
chi Kikai, Tokyo, Japan) by using the tail cuff method
without warming, as described in a previous study [16].
At least six measurements were taken for each rat. The
individual systolic BP was calculated as the mean of four
consistent readings of the systolic BP.
Treatment with a single oral dose of l-tryptophan
After 1 week of acclimatization, 9-week-old rats were
divided into a control group and an L-Trp group. After
fasting, the rats for 16 h, L-Trp was dissolved in 0.9%
saline and 100 mg L-Trp·kg
-1 body weight was orally
administered via a gastric tube to the L-Trp group,
while 1 ml of 0.9% saline was administered to the con-
trol group. BP was measured and blood samples from
tail veins were collected before and 1, 2, 4, and 6 h after
treatment for blood glucose and insulin analyses. After 1
week, the rats were treated again in the same manner,
anesthetized with diethyl ether 4 or 6 h later, and then
sacrificed. Finally, livers were dissected for mRNA
analysis.
Continuous treatment with l-tryptophan
We divided 9-week-old SHRSP into three groups and
fed them an AIN-93M-based diet for 3 weeks. The diet
of the control group was not supplemented, whereas the
diets of the other two groups were supplemented with
L-Trp at 200 mg·kg
-1 (LT200) or 1000 mg·kg
-1
(LT1000). The rats were allowed to consume these diets
and drink water ad libitum. Their food intake was
recorded every day. Each week, their systolic BP and
body weight were measured, and blood samples from
their tail veins were collected for blood glucose and
insulin analyses. At the end of the experiment, the rats
were anesthetized with diethyl ether after 16 h of fasting
and then sacrificed. Immediately afterward, blood was
collected from the abdominal aorta, and plasma was
separated by centrifugation and stored at -20°C until
analysis. For mRNA analysis, the liver of each rat cut
into 0.5 cm sections then immediately transferred into a
tube containing RNA-later solution and incubate at 4°C
over night prior to storing the samples at -20°C as the
manufacturer’s instruction (Applied Biosystems Co.,
Tokyo, Japan).
Analytical procedures
Plasma levels of total cholesterol, triacylglycerol, NEFA,
HDL-cholesterol, glucose, blood urea nitrogen, and crea-
tinine levels were measured by colorimetric enzymatic
methods (Wako Pure Chemical Co.). The LDL-choles-
terol level was calculated according to the Friedewald
formula: LDL-C = (TC - HDL-C) - (1/5 × TG) [17].
Plasma insulin levels were measured using a rat insulin
ELISA kit (Shibayagi Co., Gunma, Japan). Similarly,
plasma serotonin levels were determined using an
ELISA kit (Immunotech Co., Marseille, France). The
nitric oxide (NO) level in the plasma was quantified
using a colorimetric NO2/NO3 Assay Kit-C II (Dojindo,
Kumamoto, Japan), which is based on the Griess
method, as described in a previous study [18]. We also
estimated insulin resistance (IR) with the homeostatic
model assessment-insulin resistance (HOMA-IR) index,
which is defined as HOMA-IR = (fasting insulin level
(μU·ml
-1) × fasting glucose level (mmol·l
-1))/22.5 [19].
RNA preparation and quantitative real-time polymerase
chain reaction
Total RNA was isolated from liver samples using Isogen,
a guanidine isothiocyanate-based reagent (Nippon Gene,
Japan). The amount and purity of the isolated RNA
were determined by spectrophotometric analysis at 260
and 280 nm (ratio of 260 nm/280 nm ≥ 1.9) and agarose
gel electrophoresis (ratio of 28S RNA/18S RNA ≥ 1.5).
Five micrograms of total RNA were used as a template
to synthesize the cDNA. The RNA was denatured using
oligo-dT, random primers, and 10 mM dNTPs
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min. Then, the RNA was added to a 20-μl reaction that
contained 50 mM Tris-HCl buffer (pH 8.3), 0.1 M
dithiothreitol, 50 units SuperScript III reverse transcrip-
tase (Invitrogen, Carlsbad, CA, USA), and 20 units RNa-
seOUT RNase inhibitor (Invitrogen). This reaction was
incubated at 25°C for 5 min, 50°C for 60 min, and 70°C
for 15 min. Aliquots of the cDNA product were used as
the template for quantitative real-time polymerase chain
reaction (RT-PCR) analysis, which was performed using
an Applied Biosystems 7300 Real Time PCR System
(Foster City, CA, USA) and SYBR Premix Ex Taq
(Takara Bio Inc., Shiga, Japan). The relative gene expres-
sion levels were normalized to the amount of eukaryotic
elongation factor-1a1( EF-1) mRNA [20]. The expres-
sion of EF-1 was unaffected by group treatment. The
primer sequences were as follows: EF-1,5 ’-GAT
GGCCCCAAATTCTTGAAG-3’ (forward) and 5’-GGA
CCATGTCAACAATTGCAG-3’ (reverse); glucokinase
(Gck), 5’-GTGGCAATGGTGAACGACAC-3’ (forward)
and 5’-AATGTCGCAGTCGGTGACAG-3’ (reverse);
phosphoenolpyruvate carboxykinase 1 (Pck1), 5’-GATG
ACATTGCCTGGATGAAGTTT-3’ (forward) and 5’-TG
GGTTGATGGCCCTTAAGT-3’ (reverse); fructose
bisphosphatase 1 (Fbp1), 5’-CCACCAGAAGGCAC
CAGTTATC-3’ (forward) and 5’-AACTCCTGCA
CGTCTTCGGT-3’ (reverse); liver-type pyruvate kinase
(Pklr), 5’-GGCAGATGATGTGGATCGAAG-3’ (for-
ward) and 5’-GCCAACCTGTCACCACAATC-3’
(reverse). Amplified DNA was purified by polyacryla-
mide gel electrophoresis and cloned into pT7 blue clon-
ing vector. After transmission in E.coli,c l o n e dD N A
fragment was sequenced by using ABI dye terminator
sequencing kit and ABI310 DNA sequencer.
Data analysis
Results were expressed as means ± SEM. Statistical ana-
lyses were performed with ANOVA and Fisher’st e s t s .
The P value cutoff for statistical significance was defined
as P < 0.05. For the single dose experiment, the differ-
ences between group means were evaluated by Student’s
t test (SPSS statistical package, version 11.0). Differences
were considered statistically significant when P < 0.05.
Results
Treatment with a single oral dose of l-tryptophan
We determined whether a single oral dose of L-Trp
could lower high BP and high blood glucose levels in
SHRSP. In the control group, after the administration of
saline, the systolic BP in SHRSP remained almost con-
stant for 6 h. In contrast, in the treatment group, these
levels decreased 1 and 2 h after the administration of
saline and L-Trp and then returned to basal levels in
the control group after 4 h (Figure 1A). In addition, 4
and 6 h after treatment, blood glucose levels decreased
significantly (Figure 1B). Consistent with this result,
plasma insulin levels were also significantly lower at the
same time points (Figure 1C). Moreover, 4 and 6 h after
treatment, the HOMA-IR indices of the L-Trp group
were significantly lower than those of the control group
(Figure 1D). The effects of a single dose of L-Trp on the
level of hepatic mRNA expression are given in Addi-
tional file 1, Table S1: A single oral dose effect of L-Trp
on hepatic gene expression levels expressed as relative
changes determined by quantitative RT-PCR. A single
oral dose of L-Trp did not significantly alter the mRNA
expression of all of the genes tested.
Continuous treatment with l-tryptophan
A tt h ee n do ft h ee x p e r i m e n t a lp e r i o d ,t h e r ew e r en o
differences in the final body weight, body weight gain,
or daily food intake (Additional file 2, Table S2: Effect
of diet on food intake, weight gain, and final body
weight). The intake of L-Trp was 3.92 ± 0.08 and 19.67
± 0.59 mg·d
-1 in the LT200 and LT1000 groups, respec-
tively. Furthermore, the plasma and hepatic lipids and
renal function parameters were similar among the three
groups (data not shown). However, continuous treat-
ment with L-Trp lowered BP. In the LT1000 group, the
systolic BP of SHRSP was significantly lower than that
of the control rats during the treatment period (Figure
2A); however, in the LT200 group, the systolic BP of the
SHRSP significantly decreased after 1 week of treatment.
Consistent with this result, the plasma NO level was sig-
nificantly higher in the LT1000 group but not in the
LT200 group (Figure 2B). We also analyzed blood glu-
cose levels during the treatment period. In both treat-
ment groups, L-Trp significantly improved blood
glucose levels after 2 or 3 weeks of treatment (Figure
3A). Similar to the single dose of L-Trp, plasma insulin
levels also significantly decreased after 2 or 3 weeks of
treatment (Figure 3B). Also the HOMA-IR index in Fig-
ure 3C was not significantly modified by continuous
treatment with L-Trp. In addition, plasma serotonin
levels in the two L-Trp groups were higher than those
in the control group (Figure 4). We also measured the
hepatic mRNA expression levels of Gck, Pck1, Fbp1, and
Pklr (Additional file 3, Table S3: Continuous treatment
effect of L-tryptophan on hepatic gene expression levels
expressed as relative changes determined by quantitative
RT-PCR). The mRNA expression levels of Gck, Pck1,
Fbp1,a n dPklr in both L-Trp groups and the level of
Gck in the LT1000 group did not significantly differ
from those in the control group.
Discussion
Our results demonstrated that both single oral dose
administration and continuous treatment of L-Trp
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This is the first study about the potential efficacy of oral
L-Trp to prevent metabolic disorders using SHRSP as
an animal model of severe hypertension and multisys-
tem end-organ damage, especially in the kidney [21].
In the continuous treatment experiment, we found
that the LT1000 group exhibited significantly lower BP
one week after the administration of L-Trp. This effect
was more pronounced in the LT1000 group than in the
LT200 group, which only showed a weak antihyperten-
sive effect; these data suggest that the effect of L-Trp
may be dose-dependent. However, the blood glucose,
insulin, and serotonin levels were almost the same in
both L-Trp groups, so L-Trp did not have a dose-
dependent effect on these levels. The underlying
mechanism for the absence of a dose-dependent effect is
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due to the nature of in vivo experiments, which are
more complex and therefore make it difficult to identify
dose-dependent effects compared to in vitro
experiments.
We observed that continuous treatment of 1000
mg·kg
-1 L-Trp significantly increased plasma NO levels
(Figure 2B), which was consistent with the antihyperten-
sive effect on SHRSP (Figure 2A). Most likely, enhanced
plasma NO levels result in the vasodilator response of
L-Trp. Our results are consistent with previous studies,
which show that certain peptide substances significantly
affect NO production and cause vasodilation [22,23]. In
addition, we previously inferred that the increased
plasma NO level is a consequence of the antihyperten-
sive effect in SHRSP [18,23]. As a result, we concluded
that L-Trp might enhance vasodilation in SHRSP; how-
ever, further investigation is needed to elucidate the
underlying mechanism.
Since serotonin is synthesized from L-Trp, we tested
whether plasma serotonin levels mediated the effect of
L-Trp on blood glucose, insulin levels, and BP. Our
results indicate that increased plasma serotonin levels in
the L-Trp groups (Figure 4) might cause significantly
reduced blood glucose levels and BP in SHRSP. Many
previous studies have shown that serotonin induces a
hypoglycemic effect by stimulating the 5-HT7 receptor
in the rat adrenal gland, enhancing b-endorphin release
and glucose uptake in skeletal muscle [11,24,25]. A
recent study showed that a lack of serotonin in the b
cells of Tph1
-/- transgenic mice reduces insulin secretion
[26]. This finding suggests that serotonin is involved in
the clinical progression of diabetes and may be the basis
of novel anti-diabetic treatments. Our results are consis-
tent with a previous study that demonstrated that the
decrease in BP after the administration of L-Trp is
mediated by serotonin [27]. Furthermore, our results
imply that L-Trp can improve the regulation of glucose
metabolism and blood pressure via plasma serotonin
levels.
Our results have shown the evidence that L-Trp sup-
plementation can increase insulin sensitivity followed by
decreasing plasma insulin levels in single oral dose and
continuous treatment of L-Trp (Figures 1C and 3B). As
shown by the HOMA-IR indices, L-Trp supplementa-
tion increased insulin sensitivity more than the control
diet (Figures 1D and 3C). Therefore, since SHRSP is ani-
mal model shows insulin resistance [15], the decreasing
of plasma glucose and insulin levels in both studies and
HOMA-IR of single oral dose of L-Trp administration
indicates that L-Trp supplementation contributes to
increase insulin sensitivity of the rats. To elucidate the
mechanism of these physiological effects, we measured
the effect of L-Trp on the hepatic mRNA expression
levels of enzymes that are involved in glyconeogenesis
and glycolysis, such as Gck, Pck1,a n dFbp1. The mRNA
levels of Gck were not significantly altered in this study.
The expression of Gck was not even increased with
LT1000 treatment.
In conclusion, we determined that single oral dose
administration or continuous treatment of L-Trp
reduced blood pressure and improved insulin sensitivity
in SHRSP. Our results suggest that the effect of L-Trp
on improving the physiological and biochemical para-
meters of metabolic disorders may be mediated by
increased plasma serotonin levels. These results suggest
that L-Trp might be a potential functional food supple-
ment to help prevent metabolic disorders.
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